$1.32
+0.01 (+0.76%)
Open$1.30
Previous Close$1.31
Day High$1.35
Day Low$1.26
52W High$3.19
52W Low$0.87
Volume—
Avg Volume569.4K
Market Cap82.69M
P/E Ratio—
EPS$-0.71
SectorBiotechnology
Analyst Ratings
Strong Buy
7 analysts
Price Target
+1,565.9% upside
Current
$1.32
$1.32
Target
$21.99
$21.99
$18.66
$21.99 avg
$31.61
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 31.19M | 31.61M | 26.89M |
| Net Income | 2.24M | 2.16M | 1.99M |
| Profit Margin | 7.2% | 6.8% | 7.4% |
| EBITDA | 3.54M | 3.42M | 2.98M |
| Free Cash Flow | 1.72M | 2.00M | 2.13M |
| Rev Growth | -3.9% | +21.8% | -6.2% |
| Debt/Equity | 0.32 | 0.27 | 0.29 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $210.39 | -0.18% | 88.1 | 372.39B |
| AMGN | Amgen Inc | $326.31 | -2.95% | 23.0 | 179.23B |
| GILD | Gilead Sciences Inc | $129.58 | -1.88% | 17.4 | 160.50B |
| VRTX | Vertex Pharmaceuticals Inc | $436.95 | -2.99% | 26.4 | 114.32B |
| REGN | Regeneron Pharmaceuticals | $698.25 | -2.05% | 16.7 | 73.89B |
| ALNY | Alnylam Pharmaceuticals Inc | $286.98 | -2.20% | 66.6 | 38.43B |